PAION AG: Remimazolam: short-acting anesthetic. Ph 3 study in procedural sedation in US. Safety data in ASA III/IV patients in Ph 3 colonoscopy study and Ph 3 bronchoscopy study. US approval filed by partner Cosmo Pharmaceuticals in June 2019. Initiated Ph 3 in general anesthesia in EU in July 2018, exp completion 2019.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase III
Disease Space
Central Nervous System, Pain
Finance
Pre-earnings
Industry
Biotechnology, Specialty Pharmaceutical
Listing
Public, USA
Market Cap
100MM - 500MM
Website:
Address:
Martin Strasse 10
Aachen
Germany

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Hamptons CEO Roundtable 2019

Bridgehampton, August 15, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.